Test dell'aggiunta di M6620 (VX-970, Berzosertib) alla solita chemioterapia e radiazioni per il cancro della testa e del collo
Uno studio di fase I su M6620 (VX-970, Berzosertib) in combinazione con cisplatino e XRT in pazienti con carcinoma a cellule squamose della testa e del collo localmente avanzato (HNSCC; SDC 10060121)
This phase I trial studies the side effects and best dose of berzosertib (M6620) when given together with cisplatin and radiation therapy in treating patients with head and neck squamous cell carcinoma that has spread from where it started to nearby tissue or lymph nodes (locally advanced). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving M6620 together with cisplatin and radiation therapy may work better in treating patients with locally advanced head and neck squamous cell carcinoma.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
- Carcinoma a cellule squamose della testa e del collo
- Carcinoma a cellule squamose dell'ipofaringe in stadio IV AJCC v7
- Carcinoma laringeo a cellule squamose in stadio IV AJCC v7
- Carcinoma a cellule squamose della cavità orale in stadio IV AJCC v6 e v7
- Carcinoma orofaringeo a cellule squamose stadio IV AJCC v7
- Carcinoma a cellule squamose dell'ipofaringe in stadio III AJCC v7
- Carcinoma laringeo a cellule squamose in stadio III AJCC v6 e v7
- Carcinoma a cellule squamose della cavità orale in stadio III AJCC v6 e v7
- Carcinoma orofaringeo a cellule squamose stadio III AJCC v7
- Carcinoma della testa e del collo di origine sconosciuta
- Carcinoma a cellule squamose sinonasali in stadio III AJCC v6 e v7
- Carcinoma a cellule squamose sinonasali in stadio IV AJCC v7
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. Assess the safety and tolerability of M6620 (VX-970, berzosertib) when administered along with weekly cisplatin and radiation therapy (XRT) in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC).
II. Establish the recommended phase 2 dose (RP2D) of the combination.
SECONDARY OBJECTIVES:
I. Characterize the pharmacokinetic (PK) profile of M6620 (VX-970, berzosertib).
II. Assess for potential drug-drug interaction between M6620 (VX-970, berzosertib) and aprepitant.
III. To observe and record anti-tumor activity. IV. To assess the rate of complete metabolic response (CMR) at 12 weeks post completion of chemoradiation using 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) scans.
V. To collect archival tumor material for retrospective analysis of association between tissue-based biomarkers and clinical outcome.
OUTLINE: This is a dose-escalation study of berzosertib.
Patients receive berzosertib intravenously (IV) over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo computed tomography (CT), PET/CT, or magnetic resonance imaging (MRI) throughout the study.
After completion of study treatment, patients are followed up for 30 days, every 2 weeks for 3 months, and then every 3 months for 2 years.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
California
-
Duarte, California, Stati Uniti, 91010
- City of Hope Comprehensive Cancer Center
-
Sacramento, California, Stati Uniti, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06520
- Yale University
-
New Haven, Connecticut, Stati Uniti, 06510
- Smilow Cancer Center/Yale-New Haven Hospital
-
Trumbull, Connecticut, Stati Uniti, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Stati Uniti, 21201
- University of Maryland/Greenebaum Cancer Center
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Wayne State University/Karmanos Cancer Institute
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Rutgers Cancer Institute of New Jersey
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Case Western Reserve University
-
Columbus, Ohio, Stati Uniti, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- UPMC Hillman Cancer Center
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22908
- University of Virginia Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed head and neck squamous cell cancer (HNSCC) including paranasal sinus cancers but excluding nasopharyngeal carcinomas
- Clinical staged III or IV HNSCC, according to American Joint Committee on Cancer (AJCC) 7th Edition, that is not amenable to surgical resection
- Carcinoma of the neck of unknown primary site origin (regardless of HPV/p16 status) is eligible
- Age >= 18 years; because no dosing or adverse event data are currently available on the use of M6620 (VX-970, berzosertib) in combination with cisplatin in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Life expectancy of greater than 3 months
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
- Leukocytes >= 3,000/mcL
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- The effects of M6620 (VX-970, berzosertib) on the developing human fetus are unknown; for this reason and because DNA-damage response (DDR) inhibitors as well as other therapeutic agents used in this trial may have teratogenic potential, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after completion of M6620 (VX-970, berzosertib) administration
- Ability to understand and the willingness to sign a written informed consent document
- Women of childbearing potential who are sexually active should be willing and able to use medically acceptable forms of contraception throughout the treatment phase of the trial and for up to 6 months following the last administration of study treatment; men who are sexually active must be willing and able to use medically acceptable forms of contraception throughout the treatment phase of the trial and for 6 months after completion of M6620 (VX-970, berzosertib) administration
Exclusion Criteria:
-
Patients with nasopharyngeal carcinoma, skin squamous cell carcinoma (SCC), and salivary gland carcinomas are not eligible
-
Patients who are receiving adjuvant chemoradiation after surgical resection of the primary site of disease
-
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
-
Patients who are receiving any other investigational agents
-
Patients on tacrolimus or any other immunosuppressants with significant interaction with cisplatin
-
Patient who requires live vaccine administration
-
Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970, berzosertib) or cisplatin
-
Prior systemic chemotherapy for the current cancer (prior chemotherapy for a different cancer is allowed)
-
Prior receipt of radiotherapy that would result in overlap of the new and old radiation therapy fields
-
Uncontrolled intercurrent illness including, but not limited to:
- Ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation
- Symptomatic congestive heart failure (requiring hospital stay within the last 6 months)
- Myocardial infarction within the last 6 months
- Unstable angina pectoris, cardiac arrhythmia
- Psychiatric illness/social situations that would limit compliance with study requirements
-
Pregnant women are excluded from this study because M6620 (VX-970, berzosertib) as a DNA-damage response (DDR) inhibitor may have the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M6620 (VX-970, berzosertib), breastfeeding should be discontinued if the mother is treated with M6620 (VX-970, berzosertib); these potential risks may also apply to other agents used in this study
-
Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible because of the potential for pharmacokinetic interactions; patients with poorly controlled HIV are not eligible due to the increased risk of lethal infections when treated with marrow-suppressive therapy
-
Definitive clinical or radiographic evidence of distant metastasis or adenopathy below the clavicles
-
M6620 (VX-970, berzosertib) is primarily metabolized by CYP3A4; therefore, concomitant administration with strong inhibitors or inducers of CYP3A4 should be avoided; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Treatment (berzosertib, cisplatin, radiation therapy)
Patients receive berzosertib IV over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, PET/CT, or MRI throughout the study. |
Correlative studies Given IV
Altri nomi:
Undergo MRI
Altri nomi:
Undergo CT or PET/CT
Altri nomi:
Undergo PET/CT
Altri nomi:
Given IV
Altri nomi:
Undergo radiation therapy
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants Experiencing Grade 3, 4, and 5 Adverse Events
Lasso di tempo: Up to 6.5 years
|
According to the Cancer Therapy Evaluation Program National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v. 5). The highest grade experienced by the participant will be reported. |
Up to 6.5 years
|
|
Number of Participants Experiencing a Dose Limiting Toxicities
Lasso di tempo: Up to 3 weeks after completion of radiation therapy
|
Dose limiting toxicities are protocol-specific adverse events considered at least possibly related to the study intervention. Graded according to NCI CTCAE v5. |
Up to 3 weeks after completion of radiation therapy
|
|
Establish the Recommended Phase 2 Dose (RP2D)
Lasso di tempo: Up to 7 weeks
|
Defined as the highest doses of cisplatin and berzosertib safely combined with radiation. |
Up to 7 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pharmacokinetic Characteristics of Berzosertib
Lasso di tempo: Up to Day 5
|
The maximum concentration ratio between Day -7 collections to Day 2 collections. Collection time points are baseline, 30 and 55 minutes after the start of M6620 infusion, 5, 15, 30 minutes, 1, 2, 4, 23 (Day 3), 48 (Day 4), and 72 hours (Day 5) after the end of M6620 infusion given on Day 2. |
Up to Day 5
|
|
Potential Drug-drug Interaction
Lasso di tempo: Up to Day 5
|
The maximum concentration of M6620 in the blood when aprepitant is also given. |
Up to Day 5
|
|
Number of Participants Experiencing a Response
Lasso di tempo: Up to 6.5 years
|
Evaluated by Response Evaluation Criteria in Solid Tumors 1.1. Response is defined as complete response (disappearance of all target and non-target lesions) or partial response (at least a 30% decrease in the sum of diameters of target lesions from baseline). |
Up to 6.5 years
|
|
Number of Participants Experiencing a Metabolic Response
Lasso di tempo: At week 12 after completing intervention
|
Assessed by fluorodeoxyglucose-positron emission tomography (FDG PET) and measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Metabolic response are participants demonstrating a complete response (disappearance of all target and non-target lesions) or a partial response (at least a 30% decrease in the sum of diameters of target lesions from baseline). |
At week 12 after completing intervention
|
|
Expression of Tissue-based Biomarkers as Markers of Deoxyribonucleic Acid Damage and Predictors of Clinical Outcome
Lasso di tempo: Up to 6.5 years
|
Kaplan-Meier curves for Progression Free Survival (PFS), defined as time to disease progression, and Overall Survival (OS), defined as time until death or off study, were used to evaluate if the gene expression profiles of ERCC1 and XRCC1, and TP53 correlated to these outcomes. |
Up to 6.5 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Taofeek K Owonikoko, JHU Sidney Kimmel Comprehensive Cancer Center LAO
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Carcinoma
- Carcinoma, cellule squamose
- Carcinoma a cellule squamose della testa e del collo
- Tecniche investigative
- Terapie
- Fenomeni fisici
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Elementi
- Metalli
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Metalli, pesante
- Composti di platino
- Elementi di transizione
- Cisplatino
- 1,2-diamminocicloesaneplatino II citrato
- Radioterapia
- Radiazione
- Spettroscopia di risonanza magnetica
- Platino
- berzosertib
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NCI-2015-01643
- UM1CA186691 (Sovvenzione/contratto NIH degli Stati Uniti)
- UM1CA186690 (Sovvenzione/contratto NIH degli Stati Uniti)
- N01CM00100 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2015-01643 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- 9950 (Altro identificatore: CTEP)
- 9950 (Altro identificatore: JHU Sidney Kimmel Comprehensive Cancer Center LAO)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .